| Literature DB >> 27707913 |
Rosa Garcia-Verdugo1, Michael Erbach1, Oliver Schnell1,2.
Abstract
Since the FDA requirement for cardiovascular safety of all new antihyperglycemic drugs to enter the market, the number and extent of phase 3 clinical trials has markedly increased. Unexpected trial results imply an enormous economic, personal and time cost and has deleterious effects over R&D. To prevent unforeseen developments in clinical trials, we recommend performing a comprehensive prospective outcome scenario analysis before launching the trial. In this commentary, we discuss the most important factors to take in consideration for prediction of clinical trial outcome scenarios and propose a theoretical model for decision making.Entities:
Keywords: clinical trials; outcome prediction; scenario analysis
Mesh:
Substances:
Year: 2016 PMID: 27707913 PMCID: PMC5478029 DOI: 10.1177/1932296816670925
Source DB: PubMed Journal: J Diabetes Sci Technol ISSN: 1932-2968